Saltar al contenido principal
xMedica

NCT07570316ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…

Fase 3230 participantes buscados35 centros3 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 18 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.

How this score is built
  • Enrolment23/40

    230 participants (target)

  • Site count15/25

    18 sites

  • Country count7/15

    2 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale7/10

    argenx has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Afecciones

  • Graves' Disease
  • Graves Disease

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF. * Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening. * Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening. * Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. Exclusion Criteria: * History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter). * History of RAI (radioactive iodine) therapy or received a total thyroidectomy. * T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \<6 weeks before screening. * Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications. * Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción230 participantes buscados

Patrocinador y colaboradores

  • argenx Patrocinador

Grupos e intervenciones

  • Part A - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part B - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part B - placebo PH20 SC PFSEXPERIMENTAL

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part C - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Intervenciones

  • Biológico Efgartigimod PH20 SC

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Otro Placebo PH20 SC

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Variables de resultado

  1. Variable de resultado principal

    Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A

    Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs

    Plazo Up to 24 weeks (part A)

  2. Variable de resultado secundaria

    Time to becoming euthyroid off ATDs in part A

    ATDs: antithyroid drugs

    Plazo Up to 24 weeks (part A)

  3. Variable de resultado secundaria

    Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A

    MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Plazo Up to 24 weeks (part A)

  4. Variable de resultado secundaria

    Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A

    ULN : upper limit of normal; ATDs: antithyroid drugs.

    Plazo Up to 24 weeks (part A)

  5. Variable de resultado secundaria

    Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A

    TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

    Plazo Up to 24 weeks (part A)

  6. Variable de resultado secundaria

    Time to becoming euthyroid off ATDs and TRAb seronegative

    ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

    Plazo Up to 24 weeks (part A) + up to 135 weeks

  7. Variable de resultado secundaria

    Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)

    ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Plazo Up to 24 weeks (Part A)

  8. Variable de resultado secundaria

    Time to becoming euthyroid

    Plazo Up to 24 weeks (part A) + up to 135 weeks

  9. Variable de resultado secundaria

    Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)

    TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

    Plazo Up to 24 weeks (part A)

  10. Variable de resultado secundaria

    Percentage of participants who remain euthyroid without ATDs

    ATDs: antithyroid drug

    Plazo Up to 74 weeks (part B)

  11. Variable de resultado secundaria

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months

    ATDs: antithyroid drug

    Plazo Up to 74 weeks (part B) + up to 135 weeks

  12. Variable de resultado secundaria

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS

    ATDs: antithyroid drug

    Plazo Up to 72 weeks (part C)

  13. Variable de resultado secundaria

    Incidence of AEs and SAEs

    AEs: adverse events ; SAEs: serious adverse events.

    Plazo Up to 135 weeks

  14. Variable de resultado secundaria

    Change in ThyPRO-39 over time

    The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

    Plazo Up to 135 weeks

  15. Variable de resultado secundaria

    Change in PROMIS-PF10a over time

    The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

    Plazo Up to 135 weeks

  16. Variable de resultado secundaria

    Efgartigimod serum concentrations over time

    Plazo Up to 24 weeks (part A) + 72 weeks (part C)

  17. Variable de resultado secundaria

    Percentage change from baseline in total IgG levels in serum over time

    IgG: immunoglobulin G

    Plazo Up to 98 weeks

  18. Variable de resultado secundaria

    Percentage change from baseline in TRAb serum levels over time

    TRAb: anti-TSHR autoantibodies.

    Plazo Up to 135 weeks

  19. Variable de resultado secundaria

    Incidence of ADA against efgartigimod in serum

    ADA: antidrug antibody(ies)

    Plazo Up to 24 weeks (part A) + up to 135 weeks

  20. Variable de resultado secundaria

    Incidence of antibodies against rHuPH20 in plasma

    rHuPH20: recombinant human hyaluronidase PH20

    Plazo Up to 24 weeks (part A) + Up to 135 weeks

  21. Variable de resultado secundaria

    Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

    NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

    Plazo Up to 24 weeks (part A) + up to 135 weeks

Fechas

Fechas
Fecha de inicio10 de junio de 2026 (real)
Finalización principal1 de junio de 2028 (estimada)
Finalización1 de mayo de 2030 (estimada)
Primera publicación6 de mayo de 2026 (real)
Última actualización3 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezseptiembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

35 centros están en reclutamiento

Georgia

Georgia
CentroCiudadEstado o regiónEstado
LLC American Hospital NetworkTbilisiEn reclutamiento
In Vitro Fertilization Center LLCTbilisiEn reclutamiento
LLC Todua ClinicTbilisiEn reclutamiento
New HospitalsTbilisiEn reclutamiento
LTD Israeli-Georgian Medical Research Clinic HealthycoreTbilisiEn reclutamiento

United Kingdom

United Kingdom
CentroCiudadEstado o regiónEstado
Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)GatesheadTyne and WearEn reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Albany Medical College Community EndocrinologyAlbanyNew YorkEn reclutamiento
University of MichiganAnn ArborMichiganEn reclutamiento
Asheville Clinical ResearchAshevilleNorth CarolinaEn reclutamiento
Profound Research LLC at Tri-City Primary CareCarlsbadCaliforniaEn reclutamiento
Research Institute of DallasDallasTexasEn reclutamiento
Metro Detroit Endocrinology CenterDearbornMichiganEn reclutamiento
Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl PasoTexasEn reclutamiento
Profound ResearchFarmington HillsMichiganEn reclutamiento
Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming IslandFloridaEn reclutamiento
The Center for Diabetes and Endocrine CareFort LauderdaleFloridaEn reclutamiento
Juno ResearchHoustonTexasEn reclutamiento
Clinic of EndocrinologyHoustonTexasEn reclutamiento
Tekton Research IrvingIrvingTexasEn reclutamiento
University of Florida Jacksonville College of MedicineJacksonvilleFloridaEn reclutamiento
Truman Medical CenterKansas CityMissouriEn reclutamiento
Ilumina Medical Research LLCKissimmeeFloridaEn reclutamiento
Johnson County Clin-Trials, Inc.LenexaKansasEn reclutamiento
Biopharma Informatic, LLCMcAllenTexasEn reclutamiento
Tekton Research - McKinneyMcKinneyTexasEn reclutamiento
Southern Endocrinology Associates PAMesquiteTexasEn reclutamiento
Oceane 7 Medical & Research Center, IncMiamiFloridaEn reclutamiento
Endocrine Associates of West Village PCNew YorkNew YorkEn reclutamiento
Diabetes Associates Medical GroupOrangeCaliforniaEn reclutamiento
Havana Research Institute LLC.PasadenaCaliforniaEn reclutamiento
Pasadena Clinical TrialsPasadenaCaliforniaEn reclutamiento
Wake Internal Medicine ConsultantsRaleighNorth CarolinaEn reclutamiento
San Jose Clinical TrialsSan JoseCaliforniaEn reclutamiento
Consano Clinical ResearchShavano ParkTexasEn reclutamiento
Alliance for Multispecialty Research, LLCWichitaKansasEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 3 de noviembre de 2026

    Centro añadido

    3 sites added (35 total)

    3235

  2. 16 de octubre de 2026

    Centro añadido

    6 sites added (32 total)

    2632

  3. 22 de septiembre de 2026

    Centro añadido

    3 sites added (26 total)

    2326

  4. 17 de septiembre de 2026

    Centro añadido

    1 site added (23 total)

    2223

  5. 12 de agosto de 2026

    Centro añadido

    4 sites added (22 total)

    1822